Report : Europe Glycomics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Enzymes, Instruments, Kits, and Reagents), Application (Drug Discovery and Development, Diagnostics, Immunology, Cancer, and Others), and End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Contract Research Organizations)
At 13.1% CAGR, the Europe Glycomics Market is speculated to be worth US$ 899.30 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Europe glycomics market was valued at US$ 428.99 million in 2022 and is expected to reach US$ 899.30 million by 2028, registering an annual growth rate of 13.1% from 2022 to 2028. Rising use of glycomics in various diseases leading to development of new treatment processes and increased glycomics research and expanding R&D investments and are the critical factors attributed to the market expansion.
As scientists have concentrated their efforts in this field, they have started to learn important details about the functions of glycans and glycosylation in the body, including cellular communication, and what these factors might reveal about disease development and diagnostics. The largest and fastest-growing application category is drug discovery and development, mostly due to the rise in R&D by pharmaceutical and biotechnology firms and the expansion of drug discovery research activities in university research institutions. Several advancements show that glycomics has the potential to provide rapid and accurate diagnostics methods that transcend diverse clinical indications and complex conditions. Therefore, the use in drug development for diseases across the region is acting as a key factor driving the glycomics market.
On the contrary, high cost of equipment and shortage of skilled professionals hurdles the growth of Europe glycomics market.
Based on product, the Europe glycomics market is segmented into enzymes, instruments, kits, and reagents. The enzymes segment held 43.9% market share in 2022, amassing US$ 188.38 million. It is projected to garner US$ 404.35 million by 2028 to expand at 13.6% CAGR during 2022–2028. The enzymes segment is further segmented into glycosidases, glycosyl transferases, sialyltransferases, neuraminidases, and others. The instruments segment is also segmented into mass spectrometers, MALDI-TOF, HPLC, lectin arrays, antibody arrays, and others. Similarly, the kits segment is segmented into glycan release kits, glycan labeling kits, glycan purification kits, and others. Furthermore, the reagents segment is segmented into oligosaccharides, monosaccharides, glycoproteins, and others.
Based on application, the Europe glycomics market is segmented into drug discovery and development, diagnostics, immunology, cancer, and others. The drug discovery and development segment held 33.6% market share in 2022, amassing US$ 144.35 million. It is projected to garner US$ 309.10 million by 2028 to expand at 13.5% CAGR during 2022–2028.
Based on end user, the Europe glycomics market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and contract research organizations. The pharmaceutical & biotechnology companies segment held 49.2% market share in 2022, amassing US$ 211.14 million. It is projected to garner US$ 453.95 million by 2028 to expand at 13.6% CAGR during 2022–2028.
Based on country, the Europe glycomics market has been categorized into the UK, Germany, France, Italy, Spain, and rest of Europe. Our regional analysis states that Germany captured 26.6% market share in 2022. It was assessed at US$ 114.21 million in 2022 and is likely to hit US$ 246.86 million by 2028, exhibiting a CAGR of 13.7% during the forecast period.
Key players dominating the Europe glycomics market are Agilent Technologies, Inc.; Asparia Glycomics; Bruker Corporation; MERCK KGaA; New England Biolabs; S-BIO (Sumitomo Bakelite Co., Ltd.); Shimadzu Corporation; Takara Bio Inc.; Thermo Fisher Scientific Inc.; and Waters Corporation among others.
- In April 2022, Bruker Corporation launched and exhibited unique and novel capabilities for spatial multiomics, single-cell proteomics, and cell-line, tissue, and plasma proteomics cancer research, at the AACR Annual Meeting 2022. Bruker also announced a partnership for the application of antibody kits for the Bruker timsTOF flex novel MALDI HiPLEX-IHC workflow for targeted protein expression profiling in tissue. Bruker’s timsTOF fleX platform integrates MALDI HiPLEX-IHC protein mapping with unbiased small molecule imaging (lipids, glycans, metabolites, xenobiotics) sections.
- In Jan 2022, Shimadzu Corporation introduced the MALDI-8030. Like the class-leading MALDI-8020, the MALDI-8030 also uses an identical innovative instrument design to produce a compact footprint, whilst still achieving performance specifications like larger, more expensive MALDI-TOF models. The added feature of a dual-polarity ion source provides further versatility for users.
Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com